GlassScriptPhysician profile
Derek W Holland
NPI 1487603817
$2,603.54
in general payments reported to CMS, 2019-2025
37 companies · $894 in 2025
The $894 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,269 · 2020: $227 · 2021: $27.37 · 2023: $51.08 · 2024: $135 · 2025: $894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,043 · Education: $37.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,042.92 |
| Education | $37.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $274.90 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $254.86 | 2019-2025 | Imfinzi, Tagrisso |
| Merck Sharp & Dohme LLC | $199.61 | 2019-2025 | Keytruda |
| Pfizer INC. | $174.16 | 2019-2025 | |
| Amgen INC. | $163.40 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $152.02 | 2019-2025 | Opdivo |
| Gilead Sciences, INC. | $136.61 | 2021-2025 | Trodelvy |
| Astellas Pharma US INC | $121.74 | 2019-2020 | |
| Kite Pharma, INC. | $110.76 | 2025 | Yescarta |
| Genzyme Corporation | $101.26 | 2019-2025 | |
| Lilly USA, LLC | $89.43 | 2019 | |
| Celgene Corporation | $77.60 | 2019-2025 | Reblozyl, Pomalyst |
| Abbvie INC. | $75.23 | 2019-2025 | |
| Daiichi Sankyo INC. | $74.01 | 2020-2025 | Enhertu |
| Taiho Oncology, INC. | $54.49 | 2019-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $44.45 | 2019 | |
| Aveo Pharmaceuticals, INC. | $44.25 | 2024 | |
| Eisai INC. | $44.08 | 2020 | |
| Rigel Pharmaceuticals, INC. | $33.57 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.33 | 2025 | Iclusig |
| Bayer Healthcare Pharmaceuticals INC. | $29.66 | 2019 | |
| Beone Medicines USA, INC. | $28.22 | 2025 | Tevimbra |
| Janssen Pharmaceuticals, INC | $23.87 | 2020 | |
| Aurobindo Pharma USA, INC. | $23.04 | 2019 | |
| Alexion Pharmaceuticals, INC. | $22.68 | 2025 | Ultomiris |
| Exelixis INC. | $21.21 | 2025 | Cabometyx |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Servier Pharmaceuticals LLC | $20.68 | 2025 | |
| Glaxosmithkline, LLC. | $19.97 | 2025 | Blenrep |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.24 | 2019 | |
| Cycle Pharmaceuticals INC | $17.87 | 2025 | Phyrago |
| Dendreon Pharmaceuticals LLC | $17.37 | 2019 | |
| Seagen INC. | $17.35 | 2020 | |
| Agios Pharmaceuticals, INC. | $16.53 | 2023 | Pyrukynd |
| Ipsen Biopharmaceuticals, INC | $16.25 | 2019 | |
| Boston Scientific Corporation | $15.45 | 2021 | |
| Incyte Corporation | $14.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Holland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.